References
- Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. (2017) 121:749–70. doi: 10.1161/CIRCRESAHA.117.311059
- Lu DY, Pozios I, Haileselassie B, Ventoulis I, et al. Clinical outcomes in patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy. J Am Heart Assoc. (2018) 7:e006657. doi: 10.1161/JAHA.117.00665
- Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Prac tice Guidelines, and the Heart Rhythm Society. Circulation 2019; 140: e333-e381.
- Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021 Sep 14;42(35):3427-3520.
- Wilkoff BL, Cook JR, Epstein AE, et al. Dual chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: Dual Chamber and VVI Implantable Defibrillator (DAVID) trial. JAMA. 2002;288:3115-3123
- Ponnusamy SS, Arora V, Namboodiri N, et al. Left bundle branch pacing: A comprehensive review. J Cardiovasc Electrophysiol. 2020 Sep;31(9):2462-2473. doi: 10.1111/jce.14681. Epub 2020 Jul 30. PMID: 32681681.